Catalyst Wire Dossier Catalyst Wire Dossier

Tarafenacin 0.2 mg

Tarafenacin · Kwang Dong Pharmaceutical Co., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Tarafenacin 0.2 mg, covering 2014-03-12 to 2014-03-12. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder. [Phase 2]

See pricing